RhumbLine Advisers’s Tempest Therapeutics TPST Stock Holding History

RhumbLine Advisers’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10	Closed	-$56K	–	2958
2017 Q1	$56K	Sell	10 -2	-17%	-$9.31K	﹤0.01%	2817
2016 Q4	$53K	Sell	12 -3	-20%	-$37.4K	﹤0.01%	2825
2016 Q3	$319K	Hold	15	–	–	﹤0.01%	2453
2016 Q2	$229K	Buy	15 +7	+88%	+$160K	﹤0.01%	2669
2016 Q1	$225K	Hold	8	–	–	﹤0.01%	2678
2015 Q4	$229K	Buy	8 +1	+14%	+$33K	﹤0.01%	2724
2015 Q3	$183K	Hold	7	–	–	﹤0.01%	2815
2015 Q2	$594K	Sell	7 -1	-13%	-$91.6K	﹤0.01%	2217
2015 Q1	$790K	Buy	8 +2	+33%	+$266K	﹤0.01%	2007
2014 Q4	$837K	Hold	6	–	–	﹤0.01%	1936
2014 Q3	$295K	Hold	6	–	–	﹤0.01%	2532
2014 Q2	$163K	Buy	+6	New	+$141K	﹤0.01%	2906

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's TPST Position: Q2 2017 in Review

RhumbLine Advisers sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 10 shares — an estimated $56K sold.

RhumbLine Advisers first reported a position in TPST in Q2 2014 and held it in 12 quarters. The position peaked at $837K in Q4 2014. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

RhumbLine Advisers reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
RhumbLine Advisers sold 10 Tempest Therapeutics shares in Q2 2017, an estimated $56K.
RhumbLine Advisers first reported a position in Tempest Therapeutics in Q2 2014 and held it in 12 quarters.
RhumbLine Advisers's Tempest Therapeutics position peaked at $837K in Q4 2014.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.